← Insider buys

Phillip Md Et Al Frost has bought stock on 376 days since Dec 2015

Director at Cocrystal Pharma, Inc., and 10 other companies

SEC CIK 0000898860 · Filings on SEC.gov ↗

$135.7MBought
$227.6MSold
Aug 5Last buy

Phillip Md Et Al Frost's record

3 months after each buy, from the first price a copier could get.

−3.7%Average
−5.8 ptsVs S&P 500
25 of 67Higher

67 buys since 2019 with 3 months of prices.

Companies

Every filing

387 filings since Jan 2016, newest first

COCPBuy

Cocrystal Pharma, Inc.

Director

$71K+3.9%Aug 5
COCPBuy

Cocrystal Pharma, Inc.

Director and 10% owner

$47K+3.0%Feb 9
COCPBuy

Cocrystal Pharma, Inc.

Director and 10% owner

$47K+3.0%Jan 2
COCPBuy

Cocrystal Pharma, Inc.

Director and 10% owner

$63K+4.0%Dec 29
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$769KNov 21
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$771KNov 20
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$759KNov 19
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$679KNov 18
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$213KOct 31
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$891KAug 8
NNUPBuy

Nocopi Technologies Inc/Md/

10% owner

$215K+15.0%Jun 10
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$170KApr 10
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$185KApr 8
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$165KApr 1
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$254KMar 28
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$348KMar 17
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$115KFeb 28
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$70KJan 28
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$220KJan 17
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$741KJan 15
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$199KDec 13
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$781KDec 11
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$305KNov 29
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$159KNov 22
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$422KNov 20
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$162KNov 14
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$127KMay 23
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$211KMay 17
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$496KFeb 28
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$992KFeb 21
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$1.5M+1.0%Feb 7
BCDASell

Biocardia, Inc.

10% owner

$56K−6.0%Jan 22
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$489KJan 19
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$386KJan 18
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$954KJan 16
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$480KJan 11
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$1.3M+1.0%Jan 8
FLNTBuy

Fluent, Inc.

10% owner

$46K+1.0%Sep 21
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$176KAug 18
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$131KAug 15
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$182KAug 10
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$1.2MAug 8
COCPBuy

Cocrystal Pharma, Inc.

Director and 10% owner

$2.0M+333.0%Apr 6
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$264KMar 23
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$1.2MMar 9
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$90KSep 27
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$92KSep 26
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$95KSep 23
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$95KSep 22
OPKBuy

Opko Health, Inc.

CEO, Chair and 10% owner

$97KSep 21
About Phillip Md Et Al Frost

Phillip Frost, M.D.

Director and 10% Owner, Cocrystal Pharma, Inc. (NASDAQ: COCP)

Phillip Frost, M.D., is a seasoned physician and biotechnology executive with decades of leadership in the pharmaceutical industry. He currently serves as Chairman and Chief Executive Officer of OPKO Health, Inc. (NYSE: OPK), a position he has held since March 2007. Previously, Dr. Frost was Chairman of the Board of Teva Pharmaceuticals (NYSE: TEVA) and led IVAX Corporation as Chairman and CEO from 1987 until its acquisition by Teva in January 2006. Earlier in his career, he chaired Key Pharmaceuticals from 1972 to 1986, overseeing its growth and sale to Schering-Plough. A co-founder of Cocrystal Pharma, Inc., Dr. Frost brings extensive expertise in pharmaceutical development, commercialization, and strategic investments.

At Cocrystal Pharma, Dr. Frost serves as a Director and 10% Owner, actively participating on the Audit, Compensation, and Nominating and Corporate Governance Committees. He has demonstrated strong commitment through recent insider transactions, including the acquisition of 20,000 shares on November 25, 2025, at an average price of $0.9406 via Frost Gamma Investments Trust (for which he is trustee), and an additional 4,000 shares on November 26, 2025, totaling approximately $3,975. These bring his indirect beneficial ownership to over 1.7 million shares through the trust and 27,100 shares directly (including restricted stock units). Dr. Frost also participated in a $1.03 million private placement in October 2025, underscoring his alignment with the company's antiviral drug pipeline advancements.

Beyond corporate roles, Dr. Frost has contributed to prestigious institutions, including the Board of Regents of the Smithsonian Institution, the Board of Trustees of the University of Miami, and the Scripps Research Institutes. His board service extends to entities like Non-Invasive Monitoring Systems and Grove Bank & Trust, reflecting a broad impact in healthcare, finance, and governance.

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.